Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
ATLANTA, Oct. 27, 2016 -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, November 3, 2016 at 4:30 p.m. ET to review the Company’s financial results for the three month period ended September 30, 2016 and will provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results the same day, prior to the conference call.
In order to participate in the conference call, please dial (877) 312-5422 (domestic) or (253) 237-1122 (international) and refer to conference ID number 8654317. The live webcast can be accessed under the Investors section of the Company’s website at www.aviragentherapeutics.com.
About Aviragen Therapeutics, Inc.
Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: vapendavir, an oral treatment for human rhinovirus upper (HRV) respiratory infections in moderate-to-severe asthmatics currently being evaluated in the Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor in Phase 2 development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.aviragentherapeutics.com.
Contacts: Mark Colonnese Executive Vice President and Chief Financial Officer Aviragen Therapeutics, Inc. (678) 221-3381 [email protected] Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 [email protected]
